ArticleMedicine2026
Mendelian randomization of plasma lipidome and temporomandibular joint disorders.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mendelian randomization (MR) was used to investigate the possible causal association between lipids (LP) and temporomandibular joint disorders (TMD). To investigate the causal relationship between circulating LP and TMD, we conducted a 2-sample MR analysis. Exposure data comprised summary statistics for 179 LP from the GeneRISK genome-wide association study (N = 7174 samples). Outcome data were derived from the FinnGen genome-wide association study for TMD (N = 185169 samples). Primary causal estimates were generated using inverse-variance weighted regression, with sensitivity analyses including MR-Egger, weighted median, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier. Robustness was assessed through pleiotropy-robust methods, heterogeneity testing, and leave-one-out analysis. Our analysis identified specific lipid species associated with temporomandibular joint disorder risk. Diacylglycerol (18:1_18:1) (odds ratio [OR] = 1.067, 95% confidence interval [CI] = 1.016-1.121, P = .010) and several triacylglycerols (TGs) were significantly associated with increased risk: TG (50:3) (OR = 1.053, 95% CI = 1.006-1.102, P = .028), TG (52:3) (OR = 1.073, 95% CI = 1.031-1.118, P = .001), TG (53:3) (OR = 1.062, 95% CI = 1.017-1.109, P = .006), TG (56:5) (OR = 1.057, 95% CI = 1.005-1.111, P = .032), and TG (56:6) (OR = 1.066, 95% CI = 1.020-1.114, P = .004). In contrast, Phosphatidylcholine (15:0_18:2) (OR = 0.953, 95% CI = 0.920-0.987, P = .007) and Phosphatidylcholine (16:0_18:2) (OR = 0.961, 95% CI = 0.928-0.996, P = .031) were associated with a reduced risk. Our MR analysis provides evidence supporting a putative causal relationship between specific plasma lipid species and the development of TMD. These findings highlight the potential role of lipid metabolism in TMD pathogenesis and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.